Compare · AMGN vs EIKN
AMGN vs EIKN
Side-by-side comparison of Amgen Inc. (AMGN) and Eikon Therapeutics Inc. (EIKN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AMGN and EIKN operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- AMGN is the larger of the two at $235.64B, about 917.5x EIKN ($256.8M).
- Over the past year, AMGN is up 29.2% and EIKN is down 67.8% - AMGN leads by 97.0 points.
- AMGN has been more active in the news (24 items in the past 4 weeks vs 7 for EIKN).
- AMGN has more recent analyst coverage (25 ratings vs 7 for EIKN).
- Company
- Amgen Inc.
- Eikon Therapeutics Inc.
- Price
- -
- -
- Market cap
- $235.64B
- $256.8M
- 1M return
- -2.57%
- -42.03%
- 1Y return
- +29.20%
- -67.83%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1983
- 2026
- News (4w)
- 24
- 7
- Recent ratings
- 25
- 7
Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and a strategic research and development collaboration with Neumora Therapeutics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Latest AMGN
- New insider Arleen Paulino claimed ownership of 6,495 shares (SEC Form 3)
- Securitize Tokenizes Anthropic Stock Onchain on First Day of Public Trading
- AMGEN ANNOUNCES POSITIVE PHASE 3 RESULTS FOR DAZODALIBEP IN SJÖGREN'S DISEASE
- FDA Approval for KANJINTI issued to AMGEN INC
- Director Ishrak Omar was granted 152 shares, increasing direct ownership by 2% to 7,682 units (SEC Form 4)
- Director Holley Charles M was granted 185 shares, increasing direct ownership by 1% to 13,262 units (SEC Form 4)
- Director Gibbs David W was granted 278 shares (SEC Form 4)
- Director Drake Michael V was granted 114 shares, increasing direct ownership by 2% to 6,030 units (SEC Form 4)
- NEW DATA AT AHA 2026 DEMONSTRATES THE VALUE OF TREATMENT WITH REPATHA® EARLIER IN THE CARDIOVASCULAR RISK CONTINUUM
- Indices Hunt for Support After Steep Weekly Losses as Volatility Gauge Stays Elevated
Latest EIKN
- Eikon Therapeutics Announces Clearance to Proceed with First-in-Human Phase 1/2 Study for Novel Androgen Receptor Antagonist EIK1006 in Advanced Metastatic Prostate Cancer
- SEC Form 10-Q filed by Eikon Therapeutics Inc.
- Eikon Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Eikon Therapeutics Reports Third Quarter 2026 Financial Results and Provides Clinical Updates
- Eikon Therapeutics to Participate in Multiple Investor Conferences in November
- SEC Form 8-K filed by Eikon Therapeutics Inc.
- Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress
- SEC Form 8-K filed by Eikon Therapeutics Inc.
- Eikon Therapeutics Presents Data from PARP1-Selective and WRN Helicase Programs at the European Society for Medical Oncology Congress
- Eikon Therapeutics Announces Availability of Seven Abstracts for Presentation at the European Society for Medical Oncology Congress